1. Medical therapy to prevent recurrence of ventricular arrhythmia in normal and structural heart disease patients.
- Author
-
Jacobson JT, Iwai S, and Aronow W
- Subjects
- Arrhythmias, Cardiac drug therapy, Arrhythmias, Cardiac etiology, Cardiovascular Agents therapeutic use, Catheter Ablation, Heart Diseases complications, Humans, Randomized Controlled Trials as Topic, Recurrence, Tachycardia, Ventricular drug therapy, Tachycardia, Ventricular etiology, Tachycardia, Ventricular therapy, Ventricular Fibrillation drug therapy, Ventricular Fibrillation etiology, Ventricular Fibrillation therapy, Ventricular Premature Complexes drug therapy, Ventricular Premature Complexes etiology, Ventricular Premature Complexes therapy, Adrenergic beta-Antagonists therapeutic use, Anti-Arrhythmia Agents therapeutic use, Arrhythmias, Cardiac therapy, Calcium Channel Blockers therapeutic use
- Abstract
Introduction: Recurrent ventricular arrhythmias (VA) are a source of significant morbidity in patients without structural heart disease (SHD) and also mortality in patients with SHD. The treatment goals for these two patient populations differ greatly. Areas covered: The secondary prevention of recurrent VA in patients without and with SHD will be reviewed, focusing on clinical data (especially randomized, controlled trials) in the literature as determined through searches in PubMed and ClinicalTrials.gov. This will include β blockers, non-dihydropyridine calcium channel blockers and antiarrhythmic drugs in both subgroups and non-antiarrhythmic medications in SHD. Expert commentary: The available options for medical therapy for VA in both normal hearts and SHD are insufficient, due to substandard efficacy and toxicities. While non-pharmacologic therapies may provide an excellent option, further drug development and randomized trials are needed, as is a reappraisal of the current mode of utilization.
- Published
- 2016
- Full Text
- View/download PDF